TRIP13 and colorectal carcinoma: Since our prior study [11] indicated that TRIP13 interacts with FGFR4 in CRC cells and suggested that this interaction was involved in CRC progression, we evaluated DCZ0415‐mediated inhibition of FGFR4 and downstream signalling in CRC cells.